{"entity":{"id":"nct06709885","kind":"trial","name":"HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer","aka":[],"tldr":"A phase 2 trial of tucidinostat (chidamide), tislelizumab and cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, now recruiting.","summary":"HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer is a phase 2, randomised interventional study registered as NCT06709885 by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, with a registry enrolment figure of 100 participants, started 2024-10-15 and due to reach its primary completion in 2025-09-30. Interventions recorded: Chidamide + Tislelizumab + chemotherapy (CapeOX ); CapeOX. Conditions listed: Colon Adenocarcinoma. Primary outcome: pCR. Colorectal eligibility wording from the registry: \"Patients with colon cancer who are assessed by abdominal contrast-enhanced CT/abdominopelvic MRI as high-risk T3 (tumor destroys muscle wall and extends to pericolonic fat, protruding more than 5 mm into adjacent mesenteric fat) or T4 (tumor penetrates the visceral peritoneal surface or directly inv\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06709885","url":"https://clinicaltrials.gov/study/NCT06709885"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["tucidinostat","tislelizumab","capox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06709885","phase":"2","setting":"HDAC Inhibitor Combination With Immunochemotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer: A Multicenter, Double-arm, Phase II Randomized Controlled Study","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06709885/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"},{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}